Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.09 | N/A | +16.67% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.09 | N/A | +16.67% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook, emphasizing the importance of ongoing research and development. They did not provide specific guidance for future quarters.
Management did not provide specific revenue figures for the quarter.
The company is focused on future product development and market opportunities.
BioCryst Pharmaceuticals reported a narrower-than-expected loss per share, but did not disclose revenue figures, which may have disappointed investors. The stock dropped 7.56% in reaction to the lack of revenue information and guidance. Investors are likely concerned about the company's future performance without clear financial targets.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ONEOK INC NEW
Feb 24, 2014